Abstract：Renal osteopathy is one of the common complications of uremia, the course of disease progresses slowly. Pathological fractures and calcification of blood vessels and soft tissues can occur in the later stage, which seriously affects the quality of life and life cycle of patients with uremia. Early identification of abnormal bone metabolism is the key to prevent and treat renal osteopathy. Bone turnover markers, mianly parathyroid hormone (PTH), can early judge the type of bone metabolism, guide drugs and predict the risk of long-term fractures risks. In this paper, the changes of calcium, phosphorus and PTH in a patient with tumor-like ectopic calcium deposition and pathological fracture hemodialysis during 5 years were reviewed, and to review the literature of other bone transformation markers, and discuss the application value of bone transformation markers in the diagnosis, classification and treatment of renal osteopathy.
宋超 鲁欢 冯志瑀▲. 一例血液透析肾性骨病合并肿瘤样异位钙沉积病理性骨折的回顾性报道[J]. 中国医药导报, 2020, 17(24): 165-168.
SONG Chao LU Huan FENG Zhiyu▲. A retrospective study of a case of hemodialysis with renal osteopathy complicated by tumor-like ectopic calcium deposition and pathological fracture. 中国医药导报, 2020, 17(24): 165-168.
[1] Beck L，Bomback AS，Choi MJ，et al. KDOQI US commentary on the 2012 KDIGO clinical practice guideline for glomerulonephritis [J]. Am J Kidney Dis，2013，62（3）：403-441.
[2] Ketteler M，Block GA，Evenepoel P，et al. Executive summary of the 2017 KDIGO Chronic Kidney Disease-Mineral and Bone Disorder（CKD-MBD） Guideline Update：what′s changed and why it matters [J]. Kidney Int，2017， 92（1）：26-36.
[3] Ho LT，Sprague SM. Women and CKD-mineral and boen disorder [J]. Adv Chronic Kidney Dis，2013，20（5）：423-426.
[4] Kidney Disease：Improving Global Outcomes CKDMBDWG. KDIGO clinical practice guideline for the diagnosis，evaluation，prevention，and treatment of Chronic Kidney Disease-Mineral and Bone Disorder（CKDMBD） [J]. Kidney Int，2009，Supplement（113）：S1-S130.
[5] Bover J，Ure?觡a-Torres P，Torregrosa JV，et al. Osteoporosis，bone mineral density and CKD-MBD complex（I）：Diagnostic considerations [J]. Nefrologia，2018，38（5）：476-490.
[6] Delanaye P，Souberbielle JC，Lafage-Proust MH，et al. Can we use circulating biomarkers to monitor bone turnover in CKD haemodialysis patients? Hypotheses and facts [J]. Nephrol Dial Transplant，2014，29（5）：997-1004.
[7] Haarhaus M，Monier-Faugere MC，Magnusson P，et al. Bone alkaline phosphatase isoforms in hemodialysis patients with low versus non-low bone turnover：a diagnostic test study [J]. Am J Kidney Dis，2015，66（1）：99-105.
[8] 张萌萌，毛未贤，马倩倩，等.骨代谢标志物在骨质疏松诊疗中的应用指南（2012年版）（日本骨质疏松症学会制定）[J].中国骨质疏松杂志，2013，19（7）：645-657.
[9] Sprague SM，Bellorin-Font E，Jorgetti V，et al. Diagnostic Accuracy of Bone Turnover Markers and Bone Histology in Patients With CKD Treated by Dialysis [J]. Am J Kidney Dis，2016，67（4）：559-566.
[10] Steiniche T，Christiansen P，Vesterby A，et al. Primary hyperparathyroidism：bone structure，balance，and remodeling before and 3 years after surgical treatment [J]. Bone，2000，26（5）：535-543.
[11] Soliman M，Hassan W，Yaseen M，et al. PTH assays in dialysis patients：Practical considerations [J]. Semin Dial，2019，32（1）：9-14.
[12] Smit MA，van Kinschot CMJ，van der Linden J，et al. Clinical Guidelines and PTH Measurement：Does Assay Generation Matter [J]？ Endocr Rev，2019，40（6）：1468-1480.
[13] Chen H，Han X，Cui Y，et al. Parathyroid Hormone Fragments：New Targets for the Diagnosis and Treatment of Chronic Kidney Disease-Mineral and Bone Disorder [J]. Biomed Res Int，2018，2018：9619253.
[14] Bover J，Ure?觡a P，Aguilar A，et al. Alkaline Phosphatases in the Complex Chronic Kidney Disease-Mineral and Bone Disorders [J]. Calcif Tissue Int，2018，103（2）：111-124.
[15] Bergman A，Qureshi AR，Haarhaus M，et al. Total and bone-specific alkaline phosphatase are associated with bone mineral density over time in end-stage renal disease patients starting dialysis [J]. J Nephrol，2017，30（2）：255-262.
[16] Magnusson P，Sharp CA，Magnusson M，et al. Effect of chronic renal failure on bone turnover and bone alkaline phosphatase isoforms [J]. Kidney Int，2001，60（1）：257-265.
[17] Wheater G，Elshahaly M，Tuck SP，et al. The clinical utility of bone marker measurements in osteoporosis [J]. J Transl Med，2013，11（1）：201.
[18] Seibel MJ. Biochemical markers of bone turnover：part I：biochemistry and variability [J]. Clin Biochem Rev，2005， 26（4）：97-122.
[19] Baim S，Miller PD. Assessing the clinical utility of serum CTX in postmenopausal osteoporosis and its use in predicting risk of osteonecrosis of the jaw [J]. J Bone Miner Res，2009，24（4）：561-574.
[20] Seibel MJ. Biochemical markers of bone turnover：partII：biochemistry and variability [J]. Clin Biochem Rev，2005， 26（4）：123-125.
[21] Yamada S，Inaba M，Kurajoh M，et al. Utility of serum tartrate-resistant acid phosphatase（TＲACP5b） as a bone resorption marker in patients with chronic kidney disease：independence from renal dysfunction [J]. Clin Endocrinol （Oxf），2008，69（2）：189-196.
[22] Shidara K，Inaba M，Okuno S，et al. Serum levels of TＲAP5b，a new bone resorption marker unaffected by renal dysfunction，as a useful marker of cortical bone loss in hemodialysis patients [J]. Calcif Tissue Int，2008，82（4）：278-287.
2020, Vol. 17 
京公网安备 11010502046598号